A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06) Meeting Abstract
| Authors: | Risi, E.; Biagioni, C.; Benelli, M.; Migliaccio, I.; McCartney, A.; Bonechi, M.; Guarducci, C.; Hilbers, F.; Di Cosimo, S.; Baselga, J.; Romagnoli, D.; Boccalini, G.; Vitale, S.; Grilli, A.; Bicciato, S.; Sotiriou, C.; Biganzoli, L.; Di Leo, A.; Malorni, L. |
| Abstract Title: | A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 25s |
| Language: | English |
| ACCESSION: | WOS:000442916000077 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.570 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 570 -- Source: Wos |
